Opko Health Inc (OPK)

670
+15(+2.35%)
  • Volume:
    787,466
  • Bid/Ask:
    671/671
  • Day's Range:
    654 - 678

OPK Overview

Prev. Close
654
Day's Range
654-678
Revenue
-
Open
654
52 wk Range
645-1,666
EPS
-0.302
Volume
787,466
Market Cap
5.2B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
722,538
P/E Ratio
-6.23
Beta
1.75
1-Year Change
-41.28%
Shares Outstanding
771,959,579
Next Earnings Date
-
What is your sentiment on Opko Health?
or
Market is currently closed. Voting is open during market hours.

Opko Health Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Opko Health Inc Analysis

Opko Health Inc Company Profile

Opko Health Inc Company Profile

  • Type:Equity
  • Market:Israel
  • ISIN:US68375N1037
  • S/N:01129543

OPKO Health, Inc. is a healthcare company. The Company’s segments include Diagnostics and Pharmaceutical. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP and hGH-CTP. It also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.

Read More

Analyst Price Target

Average6.50 (+240.31% Upside)
High8.5
Low5
Price1.91
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
  • The OPK CEO won't buy any more shares because he doesn't have any more money and he also knows that OPK is a very bad company and won't be profitable.
    1
    • It’s best to observe the no of shares that the CEO (Frost) is purchasing directly -196 mil !! or as much as $500 mil. Never seen this before and may never see it again. Note- not options, these are direct purchases
      1
      • 🚀
        0
        • Wow; I bought 3,000 shares @ $3.28 and just hit my TP at $5.0 with an impressive profit of 52% in less than a year. Thanks OPK; time to take a break :)
          1
          • when it hits $6.01, I'm grabbing my lifesaver and jumping off this ship
            1
            • stock manipulation. OPK is worthless, the hedge funds keeps shorting....
              1
              • going up for
                0
                • Ante, you are wrong again. OPK has nowhere to go. OPK is not suitable for purchase. It is only suitable for short selling.
                  0
                  • OPK falls again today. if you buy in now, you lose.
                    0
                    • hi Ray ... I am full in. parchy
                      0